Cardlytics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Cardlytics hat ein Gesamteigenkapital von $199.1M und eine Gesamtverschuldung von $257.9M, was einen Verschuldungsgrad von 129.5% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $569.0M bzw. $369.8M.

Wichtige Informationen

129.5%

Verhältnis von Schulden zu Eigenkapital

US$257.89m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$97.77m
Eigenkapital	US$199.14m
Gesamtverbindlichkeiten	US$369.81m
Gesamtvermögen	US$568.95m

Jüngste Berichte zur Finanzlage

Recent updates

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

May 31

The Power Of Cardlytics' Data Partnerships Including Bank of America

Apr 17

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Apr 10

Cardlytics: Good Prospects But Macro Uncertain

Feb 16

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

Jan 18

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Jan 04

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Oct 05

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Jun 18

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Apr 17

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Mar 03

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Jan 10

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Oct 12

Cardlytics: 6 Bear Cases To Consider

Oct 10

Cardlytics: Trying To Stem The Bleeding

Sep 27

BitPay adds Cardlytics-powered rewards program to its crypto prepaid card

Aug 10

Cardlytics slumps 16% after missing top and bottom line estimates

Aug 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: CDLXDie kurzfristigen Aktiva des Unternehmens ($218.3M) übersteigen seine kurzfristigen Passiva ($102.6M).

Langfristige Verbindlichkeiten: CDLXDie kurzfristigen Vermögenswerte des Unternehmens ($218.3M) decken seine langfristigen Verbindlichkeiten ($267.3M) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: CDLXDie Nettoverschuldung im Verhältnis zum Eigenkapital (80.4%) wird als hoch angesehen.

Schulden abbauen: CDLXDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 98.9% auf 129.5% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: CDLX auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: CDLX über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt, wenn der freie Cashflow weiterhin mit historischen Raten von 16 % pro Jahr zurückgeht

Cardlytics Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Is Cardlytics (NASDAQ:CDLX) Using Debt In A Risky Way?

Recent updates

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

Consensus EPS estimates fall by 33%

Price target decreased by 21% to US$14.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Cardlytics, Inc. to Report Q1, 2024 Results on May 08, 2024

The Power Of Cardlytics' Data Partnerships Including Bank of America

Cardlytics, Inc., Annual General Meeting, May 23, 2024

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Cardlytics, Inc. Appoints Liane Hornsey to Its Board of Directors

CEO & Director notifies of intention to sell stock

Now 35% undervalued

Consensus estimates of losses per share improve by 18%

Cardlytics, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Cardlytics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 46% to US$17.00

New major risk - Share price stability

No longer forecast to breakeven

Cardlytics, Inc. Provides Earnings Guidance for the First Quarter of 2024

CEO & Director notifies of intention to sell stock

Cardlytics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Cardlytics: Good Prospects But Macro Uncertain

High number of new directors

COO & GM of Bridg exercised options and sold US$443k worth of stock

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

CEO & Director notifies of intention to sell stock

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Kigo, LLC acquired HSP EPI Acquisition, LLC from Cardlytics, Inc. (NasdaqGM:CDLX).

CEO & Director exercised options and sold US$332k worth of stock

Consensus EPS estimates upgraded to US$1.32 loss, revenue downgraded

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Announces Resignation of Tony Weisman as Member of the Board and as Member of the Nominating and Corporate Governance Committee

Cardlytics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

Cardlytics, Inc. Appoints Alex Mishurov as Independent Director

CEO & Director recently sold US$2.9m worth of stock

Cardlytics, Inc. Announces Board Member Changes

Insider recently sold US$172k worth of stock

Consensus EPS estimates fall by 29%, revenue upgraded

Cardlytics, Inc. Provides Earnings Guidance for the Third Quarter 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Insufficient new directors

Cardlytics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Cardlytics Appoints Alexis Desieno as New Chief Financial Officer

Cardlytics, Inc. Announces Board Changes

Cardlytics, Inc. Announces Board Changes

CEO & Director notifies of intention to sell stock

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$1.87 loss, revenue downgraded

Price target increased by 9.8% to US$6.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Second Quarter of 2023

Cardlytics, Inc. (NASDAQ:CDLX) Stock Rockets 105% But Many Are Still Ignoring The Company

Price target increased by 8.9% to US$6.10

Full year 2022 earnings: EPS misses analyst expectations

Is Cardlytics, Inc. (NASDAQ:CDLX) Trading At A 38% Discount?

Price target decreased by 18% to US$7.40

Cardlytics, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Cardlytics Appoints Amit Gupta as Chief Operating Officer

Is Cardlytics (NASDAQ:CDLX) A Risky Investment?

Cardlytics, Inc. Announces Board Changes

Price target decreased to US$9.80

Co-Founder & Executive Chairman notifies of intention to sell stock

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardlytics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022